Grants and Contributions:
Title:
Development of novel single domain antibodies for cancer therapy II
Agreement Number:
916018
Agreement Value:
$350,000.00
Agreement Date:
Nov 1, 2018 - Nov 1, 2019
Description:
Cancer remains a very important disease in North America and the world. Antibodies have emerged as an effective treatment for cancer. KisoJi is developing antibodies for treatment of newly diagnosed cancers and for previously treated cancers.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Laval, Quebec, CA H7V 3S8
Reference Number:
172-2018-2019-Q3-916018
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
858257454
Recipient Type:
For-profit organization
Recipient's Legal Name:
Kisoji Biotechnologie Inc.
Federal Riding Name:
Vimy
Federal Riding Number:
24078
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254